BAKER BROS ADVISORS LLC Insider Trading Transactions
Get free email notifications about insider trading for BAKER BROS ADVISORS LLC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of BAKER BROS ADVISORS LLC. BAKER BROS ADVISORS LLC is 10% Owner in BIOCRYST PHARMACEUTICALS INC ($BCRX) and Director in INCYTE CORP ($INCY) and Director in ALEXION PHARMACEUTICALS INC ($ALXN) and 10% Owner in IDERA PHARMACEUTICALS, INC. ($IDRA) and Director in IDERA PHARMACEUTICALS, INC. ($IDRA) and in XOMA Corp ($XOMA) and Director in ACADIA PHARMACEUTICALS INC ($ACAD) and Director in SEATTLE GENETICS INC /WA ($SGEN) and Director in GENOMIC HEALTH INC ($GHDX) and 10% Owner in BELLICUM PHARMACEUTICALS, INC ($BLCM) and 10% Owner in AQUINOX PHARMACEUTICALS, INC ($AQXP) and Director in AQUINOX PHARMACEUTICALS, INC ($AQXP) and Director in Zymeworks Inc. ($ZYME) and Director in Kodiak Sciences Inc. ($KOD) and 10% Owner in Invitae Corp ($NVTA) and Director in IGM Biosciences, Inc. ($IGMS) and 10% Owner in Atreca, Inc. ($BCEL) and in Mirati Therapeutics, Inc. ($MYG) and 10% Owner in Mirati Therapeutics, Inc. ($MYG) and Director in Talis Biomedical Corp ($TLIS) and Director in Aeglea BioTherapeutics, Inc. ($AGLE) and in RHYTHM PHARMACEUTICALS, INC. ($RYTM) and in Intellia Therapeutics, Inc. ($NTLA) and Director in BeiGene, Ltd. ($BGNE) and Director in Prelude Therapeutics Inc ($PRLD) and Director in Kiniksa Pharmaceuticals, Ltd. ($KNSA) and in HOOKIPA Pharma Inc. ($HOOK).
Latest Insider Trading Transactions of BAKER BROS ADVISORS LLC
Sentiment: All, ACAD, AGLE, ALXN, BCEL, BGNE, BLCM, BCRX, GHDX, HOOK, IDRA, IGMS, INCY, NTLA, NVTA, KNSA, KOD, MYG, NLTX, PRLD, RYTM, SGEN, TLIS, XOMA, ZYME
Page: < prev 1 ... 7 8 9 10 11
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jan 26 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 10.80 | 7,318 | 79,059 | 777,652 | 770.3 K to 777.7 K (+0.95 %) |
Jan 26 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 11.20 | 2,522 | 28,257 | 6,432,847 | 6.4 M to 6.4 M (+0.04 %) |
Jan 26 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 11.20 | 278 | 3,115 | 770,334 | 770.1 K to 770.3 K (+0.04 %) |
Jan 26 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 10.98 | 4,503 | 49,423 | 6,430,325 | 6.4 M to 6.4 M (+0.07 %) |
Jan 26 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 10.98 | 497 | 5,455 | 770,056 | 769.6 K to 770.1 K (+0.06 %) |
Jan 26 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 11.23 | 2,833 | 31,822 | 6,425,822 | 6.4 M to 6.4 M (+0.04 %) |
Jan 26 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 11.23 | 312 | 3,505 | 769,559 | 769.2 K to 769.6 K (+0.04 %) |
Jan 26 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 10.69 | 25,650 | 274,219 | 6,422,989 | 6.4 M to 6.4 M (+0.40 %) |
Jan 26 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 10.69 | 2,810 | 30,041 | 769,247 | 766.4 K to 769.2 K (+0.37 %) |
Jan 26 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 10.60 | 156 | 1,654 | 6,397,339 | 6.4 M to 6.4 M (0.00 %) |
Jan 26 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 10.60 | 17 | 180 | 766,437 | 766.4 K to 766.4 K (0.00 %) |
Jan 26 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 10.69 | 4,021 | 42,999 | 6,397,183 | 6.4 M to 6.4 M (+0.06 %) |
Jan 26 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 10.69 | 440 | 4,705 | 766,420 | 766 K to 766.4 K (+0.06 %) |
Jan 26 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 10.78 | 17,221 | 185,666 | 6,393,162 | 6.4 M to 6.4 M (+0.27 %) |
Jan 26 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 10.78 | 1,887 | 20,345 | 765,980 | 764.1 K to 766 K (+0.25 %) |
Jan 25 2016 | BCRX | BIOCRYST PHARMACEU ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 7.00 | 3,200 | 22,389 | 12,553,180 | 12.5 M to 12.6 M (+0.03 %) |
Jan 25 2016 | BCRX | BIOCRYST PHARMACEU ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 7.29 | 103,600 | 755,368 | 12,549,980 | 12.4 M to 12.5 M (+0.83 %) |
Jan 20 2016 | BCRX | BIOCRYST PHARMACEU ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 6.94 | 1,325 | 9,197 | 12,446,380 | 12.4 M to 12.4 M (+0.01 %) |
Jan 20 2016 | BCRX | BIOCRYST PHARMACEU ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 6.87 | 51,370 | 352,974 | 12,445,055 | 12.4 M to 12.4 M (+0.41 %) |
Jan 20 2016 | BCRX | BIOCRYST PHARMACEU ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 7.12 | 92,200 | 656,750 | 12,393,685 | 12.3 M to 12.4 M (+0.75 %) |
Jan 20 2016 | BCRX | BIOCRYST PHARMACEU ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 7.49 | 25,000 | 187,333 | 12,301,485 | 12.3 M to 12.3 M (+0.20 %) |
Jan 20 2016 | BCRX | BIOCRYST PHARMACEU ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 7.45 | 175,000 | 1,303,890 | 12,276,485 | 12.1 M to 12.3 M (+1.45 %) |
Jan 20 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 8.90 | 1,734 | 15,433 | 6,375,941 | 6.4 M to 6.4 M (+0.03 %) |
Jan 20 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 8.90 | 190 | 1,691 | 764,093 | 763.9 K to 764.1 K (+0.02 %) |
Jan 20 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 8.96 | 27,996 | 250,766 | 6,374,207 | 6.3 M to 6.4 M (+0.44 %) |
Jan 20 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 8.96 | 3,067 | 27,472 | 763,903 | 760.8 K to 763.9 K (+0.40 %) |
Jan 20 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 8.96 | 13,789 | 123,493 | 6,346,211 | 6.3 M to 6.3 M (+0.22 %) |
Jan 20 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 8.96 | 1,511 | 13,532 | 760,836 | 759.3 K to 760.8 K (+0.20 %) |
Jan 20 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 9.89 | 57,453 | 567,934 | 6,332,422 | 6.3 M to 6.3 M (+0.92 %) |
Jan 20 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 9.89 | 6,294 | 62,217 | 759,325 | 753 K to 759.3 K (+0.84 %) |
Jan 20 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 9.15 | 14,313 | 131,017 | 6,274,969 | 6.3 M to 6.3 M (+0.23 %) |
Jan 20 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 9.15 | 1,568 | 14,353 | 753,031 | 751.5 K to 753 K (+0.21 %) |
Jan 20 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 9.21 | 10,123 | 93,282 | 6,260,656 | 6.3 M to 6.3 M (+0.16 %) |
Jan 20 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 9.21 | 1,109 | 10,219 | 751,463 | 750.4 K to 751.5 K (+0.15 %) |
Jan 20 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 9.08 | 45,903 | 416,602 | 6,250,533 | 6.2 M to 6.3 M (+0.74 %) |
Jan 20 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 9.08 | 5,029 | 45,642 | 750,354 | 745.3 K to 750.4 K (+0.67 %) |
Jan 15 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 8.56 | 47,193 | 403,930 | 6,204,630 | 6.2 M to 6.2 M (+0.77 %) |
Jan 15 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 8.56 | 5,196 | 44,473 | 745,325 | 740.1 K to 745.3 K (+0.70 %) |
Jan 15 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 8.95 | 4,949 | 44,308 | 6,157,437 | 6.2 M to 6.2 M (+0.08 %) |
Jan 15 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 8.95 | 545 | 4,879 | 740,129 | 739.6 K to 740.1 K (+0.07 %) |
Jan 15 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 8.82 | 3,279 | 28,937 | 6,152,488 | 6.1 M to 6.2 M (+0.05 %) |
Jan 15 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 8.82 | 361 | 3,186 | 739,584 | 739.2 K to 739.6 K (+0.05 %) |
Jan 15 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 8.10 | 20,851 | 168,891 | 6,149,209 | 6.1 M to 6.1 M (+0.34 %) |
Jan 15 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 8.10 | 2,296 | 18,597 | 739,223 | 736.9 K to 739.2 K (+0.31 %) |
Jan 15 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 8.08 | 2,998 | 24,213 | 6,128,358 | 6.1 M to 6.1 M (+0.05 %) |
Jan 15 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 8.08 | 330 | 2,665 | 736,927 | 736.6 K to 736.9 K (+0.04 %) |
Jan 15 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 7.91 | 12,706 | 100,517 | 6,125,360 | 6.1 M to 6.1 M (+0.21 %) |
Jan 15 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 7.91 | 1,399 | 11,067 | 736,597 | 735.2 K to 736.6 K (+0.19 %) |
Jan 15 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 8.17 | 90,550 | 739,947 | 6,112,654 | 6 M to 6.1 M (+1.50 %) |
Jan 15 2016 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 8.17 | 9,970 | 81,472 | 735,198 | 725.2 K to 735.2 K (+1.37 %) |
Dec 15 2015 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 32.50 | 15,000 | 487,500 | 15,000 | |
Sep 16 2015 | MYG | Mirati Therapeutic ... | BAKER BROS. ADVISORS LP | 10% Owner | Option Exercise | J | 6.74 | 137 | 923 | 137 | |
Sep 16 2015 | MYG | Mirati Therapeutic ... | BAKER BROS. ADVISORS LP | 10% Owner | Option Exercise | J | 6.74 | 137 | 923 | 137 | |
Sep 16 2015 | MYG | Mirati Therapeutic ... | BAKER BROS. ADVISORS LP | 10% Owner | Option Exercise | J | 6.74 | 274 | 1,847 | 0 | |
Sep 16 2015 | MYG | Mirati Therapeutic ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 45.00 | 139,220 | 6,264,900 | 2,744,052 | 2.6 M to 2.7 M (+5.34 %) |
Sep 16 2015 | MYG | Mirati Therapeutic ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 45.00 | 10,780 | 485,100 | 170,714 | 159.9 K to 170.7 K (+6.74 %) |
Sep 11 2015 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 15.50 | 2,213,469 | 34,308,770 | 6,022,104 | 3.8 M to 6 M (+58.12 %) |
Sep 11 2015 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 15.50 | 266,563 | 4,131,727 | 725,228 | 458.7 K to 725.2 K (+58.12 %) |
Jul 23 2015 | XOMA | XOMA Corp | BAKER BROS. ADVISORS LP | Sell | S | 1.09 | 229,436 | 250,659 | 90,538 | 320 K to 90.5 K (-71.70 %) | |
Jul 23 2015 | XOMA | XOMA Corp | BAKER BROS. ADVISORS LP | Sell | S | 1.09 | 9,411,311 | 10,281,857 | 3,153,539 | 12.6 M to 3.2 M (-74.90 %) | |
Jul 23 2015 | XOMA | XOMA Corp | BAKER BROS. ADVISORS LP | Sell | S | 1.09 | 1,359,253 | 1,484,984 | 467,436 | 1.8 M to 467.4 K (-74.41 %) | |
Jun 17 2015 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 39.06 | 12,500 | 488,250 | 12,500 |